<div id="readability-page-1"><p>Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) were up 0.6% during mid-day trading on Thursday . The stock traded as high as $878.09 and last traded at $872.34. Approximately 603,843 shares changed hands during trading, a decline of 79% from the average daily volume of 2,942,490 shares. The stock had previously closed at $867.30.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Hims &amp; Hers Health Soars on Generic GLP-1 Rollout Plans </li></ul><p>LLY has been the topic of several recent research reports. Cantor Fitzgerald restated an &#34;overweight&#34; rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research note on Tuesday. Morgan Stanley upped their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, February 16th. Argus boosted their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, May 14th. Truist Financial upped their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, May 1st. Finally, Jefferies Financial Group boosted their price target on Eli Lilly and Company from $925.00 to $957.00 and gave the company a &#34;buy&#34; rating in a report on Friday, June 7th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $787.53.</p><p><b>Check Out Our Latest Stock Analysis on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Stock Up 1.1 %</h2><ul><li>4 Stocks Making New Highs Despite Market Weakness</li></ul><p>The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company has a 50-day simple moving average of $781.80 and a 200 day simple moving average of $714.39. The company has a market cap of $833.23 billion, a P/E ratio of 129.19, a P/E/G ratio of 1.89 and a beta of 0.36. </p><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion for the quarter, compared to analysts' expectations of $8.94 billion. During the same period in the prior year, the business posted $1.62 earnings per share. The business's revenue for the quarter was up 26.0% on a year-over-year basis. On average, equities analysts anticipate that Eli Lilly and Company will post 13.76 EPS for the current year. </p><h2>Eli Lilly and Company Announces Dividend</h2><ul><li>LifeMD Can Surge on Its GLP-1 Offerings </li></ul><p>The company also recently announced a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.59%. The ex-dividend date was Wednesday, May 15th. Eli Lilly and Company's dividend payout ratio is 76.58%. </p><h2>Insider Activity</h2><p>In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the transaction, the insider now directly owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CAO Donald A. Zakrowski sold 750 shares of the business's stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm's stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the sale, the insider now owns 98,556,247 shares of the company's stock, valued at $79,752,700,634.87. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 552,804 shares of company stock worth $462,119,714. Company insiders own 0.13% of the company's stock. </p><h2>Institutional Trading of Eli Lilly and Company</h2><p>A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in Eli Lilly and Company by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company's stock worth $56,592,709,000 after buying an additional 1,133,810 shares during the last quarter. Capital World Investors raised its stake in shares of Eli Lilly and Company by 0.3% during the 4th quarter. Capital World Investors now owns 26,949,773 shares of the company's stock valued at $15,709,466,000 after buying an additional 89,720 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company's stock valued at $6,738,605,000 after buying an additional 83,915 shares during the period. Norges Bank acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $5,992,890,000. Finally, Northern Trust Corp increased its holdings in Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company's stock worth $5,456,314,000 after acquiring an additional 355,317 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock. </p><h2>Eli Lilly and Company Company Profile</h2> (Get Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>How to Use the MarketBeat Excel Dividend Calculator</li><li>Dave &amp; Buster’s Stock Offers a Prime Buying Opportunity</li><li>Dividend Payout Ratio Calculator</li><li>The FOMC Decision Means Higher Prices for Stocks This Summer</li><li>Dividend Capture Strategy: What You Need to Know</li><li>Here's Why Analysts Boosted Walmart Stock's Valuation</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ The Key to this $10 Trillion Tech Boom <span><span>(From Porter &amp; Company)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MzM4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MzM4"/></p><h2>Should you invest $1,000 in Eli Lilly and Company right now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

<p>Eli Lilly and Company (NYSE:LLY) stock price increased by 0.6% during mid-day trading. The company's shares traded as high as $878.09 and last traded at $872.34. The stock had a decline in trading volume. Several research reports have rated the stock as "Moderate Buy" with an average target price of $787.53. Eli Lilly and Company recently announced a quarterly dividend. Insiders have sold a significant amount of company stock.</p>

Eli Lilly and Company (NYSE:LLY) Stock Price Up 0.6%